Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

BACKGROUND: The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Reichmann, Heinz, Lees, Andrew, Rocha, José-Francisco, Magalhães, Diogo, Soares-da-Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055125/
https://www.ncbi.nlm.nih.gov/pubmed/32345378
http://dx.doi.org/10.1186/s40035-020-00187-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055125/
https://www.ncbi.nlm.nih.gov/pubmed/32345378
http://dx.doi.org/10.1186/s40035-020-00187-1

Ejemplares similares